Intuitive Surgical stock steadies as analysts trim targets

Intuitive Surgical (US46120E6023) stock is being priced against a $523.46 average target as of 27 July 2026, while RBC cut its target from $650 to $600 and Robert W. Baird cut its target from $525 to $500 in July coverage tracked by MarketBeat. The same report lists 21 Buy ratings, six Hold ratings, and one Sell rating, which keeps the consensus at Moderate Buy and gives the stock a clear analyst anchor on a quiet tape.

Target cuts to $600 and $500

RBC's move to $600 came from $650, a $50 cut, while Robert W. Baird moved to $500 from $525, a $25 reduction, both in July 2026 coverage cited by MarketBeat. Mizuho also set a $500 target on 15 July 2026, showing a cluster of lower targets even as the average still sits above those levels.

That spread matters because the average target of $523.46 is only modestly above the $500 marks, leaving the consensus closer to a narrow band than a wide upside case. For a large-cap medtech name, that kind of clustering often becomes the market's reference point for the next earnings move.

Ratings remain tilted higher

MarketBeat's summary says 21 analysts rate Intuitive Surgical a Buy, compared with 6 Hold ratings and 1 Sell rating. BMO Capital Markets reaffirmed an Outperform rating on 20 July 2026, which helps offset the recent target cuts.

The mix leaves the stock with a supportive but more cautious tone than a pure momentum setup. A lower target does not change the long-term franchise case on its own, but it does show that near-term expectations are being trimmed.

da Vinci remains the core product

The company's best-known platform is the da Vinci robotic surgery system, which remains the central product line behind the investment case. That matters because analyst target changes are still being judged against procedure growth, installed base expansion, and recurring system economics around the platform.

For a company that reports through a recurring hardware-plus-instruments model, the product franchise is the anchor that links the analyst debate to operating results. The market is therefore reacting not just to ratings, but to how much growth the da Vinci base can sustain into the next print.

Average target at $523.46

Intuitive Surgical stock was trading against the $523.46 average target cited by MarketBeat on 27 July 2026. That leaves the share price framed by a well-defined analyst range, with the $500 area now a visible floor in recent coverage.

The current setup is less about a single dramatic call and more about a recalibration across several firms. For investors, the numbers now point to a tighter consensus band rather than a broad rerating story.